[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

GIP component of tirzepatide is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.

Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.

Where I would push back on the GIP component of tirzepatide consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.

For anyone finding this later: the short answer on GIP component of tirzepatide is that it depends on one thing, and the rest of the thread is people identifying which thing.

One caution on GIP component of tirzepatide: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.

Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.

Confirming post #102 from a second method, which matters more than confirming it from a second person.

The dual agonism is not a marketing framing — GIP receptor and GLP-1 receptor engagement are both demonstrable. What is genuinely unresolved is how much of the clinical effect the GIP limb contributes, because no trial decomposes it.

Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.